Bexson biomedical and stevanato group awarded pda drug delivery innovation award

Santa barbara, calif. , oct. 19, 2022 /prnewswire/ -- bexson biomedical, inc., a biopharmaceutical company focused on disrupting the $189 billion small molecule injectable market and enabling home health solutions, today announced bexson and stevanato group  (nyse: stvn), a leading global provider of drug containment and delivery solutions to the pharmaceutical, biotechnology, and life sciences industries, have been jointly awarded the parenteral drug association's (pda) 2022 drug delivery innovation partnership award.
STVN Ratings Summary
STVN Quant Ranking